The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Gu´erin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral resection of bladder tumour (TURBT) and mostly directed towards patients with highgrade tumours, T1 tumours, and in situ carcinomas. However, from 20% to 40% of the patients do not respond and frequently present tumour progression. Since BCG effectiveness is unpredictable, it is important to find consistent biomarkers that can aid either in the prediction of the outcome and/or side effects development. Accordingly, we conducted a systematic critica...
AbstractIntravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred first line treatment fo...
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for...
Objectives With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers...
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over t...
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over t...
Objectives To investigate the predictive value of different immunological markers on treatment outco...
Aim: Bacillus Calmette-Guerin (BCG) is a standard treatment for reducing tumour recurrence and delay...
Obwohl die intravesikale Bacillus-Calmette Guérin (BCG) Therapie immer noch die wirksamste Immunther...
With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been i...
It was with great interest that we read the article by Zuiverloon et al that was recently published ...
With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been i...
CONTEXT: Bacillus Calmette-Guerin (BCG) is currently the most effective intravesical therapy for non...
Intravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred first line treatment for non-mu...
Aim: Intravesical Bacille Calmette-Guérin (BCG) is the mainstay adjuvant treatment of non-muscle-inv...
OBJECTIVE: To evaluate the predictive value of genetic polymorphisms in the context of BCG immunoth...
AbstractIntravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred first line treatment fo...
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for...
Objectives With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers...
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over t...
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over t...
Objectives To investigate the predictive value of different immunological markers on treatment outco...
Aim: Bacillus Calmette-Guerin (BCG) is a standard treatment for reducing tumour recurrence and delay...
Obwohl die intravesikale Bacillus-Calmette Guérin (BCG) Therapie immer noch die wirksamste Immunther...
With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been i...
It was with great interest that we read the article by Zuiverloon et al that was recently published ...
With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been i...
CONTEXT: Bacillus Calmette-Guerin (BCG) is currently the most effective intravesical therapy for non...
Intravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred first line treatment for non-mu...
Aim: Intravesical Bacille Calmette-Guérin (BCG) is the mainstay adjuvant treatment of non-muscle-inv...
OBJECTIVE: To evaluate the predictive value of genetic polymorphisms in the context of BCG immunoth...
AbstractIntravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred first line treatment fo...
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for...
Objectives With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers...